Nutrient‑Sensing SIRT6 Controls Epigenetic Silencing of MMR Genes as an Evolved Antagonistic Pleiotropy Switch

Background

Antagonistic pleiotropy (AP) predicts that alleles favored early in life can be tolerated later if they impose costs after reproduction wanes [1]. In the colon, age‑related decline of DNA mismatch repair (MMR) and rise in microsatellite instability (MSI) exemplify this pattern [2,3]. Yet the molecular switch that silences MMR genes post‑reproductively remains unknown.

Hypothesis

We propose that the NAD⁺‑dependent deacetylase SIRT6 acts as an evolutionarily conserved sensor that actively represses MMR transcription when systemic nutrient signaling indicates a shift away from reproductive investment. In other words, SIRT6 mediates the AP trade‑off by linking metabolic state to epigenetic silencing of MMR, thereby facilitating field cancerization as a programmed, rather than stochastic, process.

Mechanistic Rationale

• SIRT6 deacetylates histone H3K9 and H3K56 at promoters of DNA repair genes, influencing their expression [4].
• NAD⁺ levels decline with age and are modulated by circadian and feeding cycles, which shift after menopause or reduced fecundity [5].
• Early‑life high mTORC1 activity, supportive of growth and reproduction, keeps NAD⁺ consumption low, permitting high SIRT6 activity elsewhere but low at MMR loci due to competing substrates.
• When reproductive signaling falls (e.g., reduced gonadotropins), NAD⁺ flux rises, SIRT6 activity increases at MMR promoters, leading to H3K9 deacetylation, chromatin compaction, and transcriptional silencing.
• This creates a permissive field for MSI, accelerating epigenetic age and CRC risk as a side‑effect of conserving resources for kin.

Testable Predictions

1. Prediction A: In post‑reproductive female mice, pharmacologic activation of SIRT6 (e.g., with MDL‑801) will maintain MMR protein levels (MLH1, MSH2) in colonic crypts compared with vehicle.
2. Prediction B: Mice with intestinal‑specific SIRT6 overexpression will show reduced MSI accumulation and lower incidence of age‑related colonic tumors, without altering litter size or early‑life growth metrics.
3. Prediction C: Conversely, conditional knockout of SIRT6 in intestinal stem cells of young, reproductively active mice will precipitate premature MMR silencing and MSI, mimicking the aged phenotype.

Experimental Approach

• Use C57BL/6J mice; monitor estrous cycles to define reproductive stage.
• Treat groups with SIRT6 activator, inhibitor, or vehicle for 6 months.
• Quantify MMR protein by immunohistochemistry and immunofluorescence in isolated crypts.
• Measure MSI using PCR‑based panels of microsatellite loci.
• Track tumor burden via colonoscopy and histopathology.
• Assess reproductive output (number of pups per litter, inter‑birth interval) to ensure early‑life fitness is unchanged.
• Parallel human validation: correlate colonic mucosal SIRT6 expression (from biopsy archives) with MSI status and epigenetic age acceleration in post‑menopausal women [6].

Potential Outcomes and Falsifiability

• If SIRT6 activation preserves MMR and reduces MSI without compromising early fecundity, the hypothesis gains support, indicating that the AP switch is druggable.
• If SIRT6 manipulation fails to affect MMR levels or MSI, or if it markedly alters litter size, the hypothesis is falsified, suggesting that MMR silencing occurs via a different, SIRT6‑independent mechanism.
• Demonstrating that SIRT6 loss in young mice accelerates MSI would further confirm its role as a deliberate, evolutionarily tuned brake on DNA repair.

By targeting the nutrient‑sensing node that couples reproductive state to MMR expression, this work reframes aging‑associated cancer risk not as inevitable damage but as a modifiable, evolutionarily programmed interface—offering a precise point where longevity medicine could negotiate with, rather than override, life‑history strategies.